EU/3/11/898: Orphan designation for the treatment of chronic non-infectious uveitis
Sirolimus
Table of contents
Overview
On 30 August 2011, orphan designation (EU/3/11/898) was granted by the European Commission to Santen Oy, Finland, for sirolimus for the treatment of chronic non-infectious uveitis.
Key facts
Active substance |
Sirolimus
|
Intended use |
Treatment of chronic non-infectious uveitis
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/11/898
|
Date of designation |
30/08/2011
|
Sponsor |
Santen Oy
Niittyhaankatu 20 FI-33720 Tampere Finland Telephone: + 358 3 284 8111 Telefax: + 358 3 318 19 00 E-mail: mail@santen.de |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Update history
Date | Update |
---|---|
August 2022 | Please note that this product was withdrawn from the Union Register of orphan medicinal products in August 2022 on request of the Sponsor. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: